Saudi Arabia Liver Diseases Therapeutics Market Report 2022 to 2030

Saudi Arabia Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Saudi Arabia Liver Disease Therapeutics market will reach a value of $685 Mn from $393 Mn in 2022, growing at a CAGR of 7.2% during 2022-2030. Liver Disease Therapeutics in Saudi Arabia is dominated by a few domestic pharmaceutical companies such as Tabuk Pharmaceuticals, Jamjoom Pharma, and SPIMACO. The Liver Disease Therapeutics market in Saudi Arabia is segmented into different types of disease and different therapy types. Some of the major factors affecting the Saudi Arabia Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10SAPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: Saudi Arabia AUTHOR: Dr. Vishwa Modhia

Buy Now

Saudi Arabia Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Saudi Arabia Liver Disease Therapeutics market will reach a value of $685 Mn from $393 Mn in 2022, growing at a CAGR of 7.2% during 2022-2030.

Saudi Arabia is a high-income, developing country in the Middle East bordering the Persian Gulf and the Red Sea. Non-alcoholic fatty liver disease (NAFLD) is also a major health concern in Saudi Arabia, with a general population prevalence of up to 30% and a prevalence of up to 75% in those with diabetes or obesity. Healthy diets reduced alcohol intake, and an increased understanding of the necessity of the hepatitis B vaccine are all vital for the prevention and management of liver disease in Saudi Arabia.

According to the latest WHO data published in 2020 Liver Disease Deaths in Saudi Arabia reached 4,931 or 3.68% of total deaths. The age-adjusted Death Rate is 26.88 per 100,000 of the population ranks Saudi Arabia 69^th in the world. Saudi Arabia's government spent 6.2 % of its GDP on healthcare in 2020.

Saudi Arabia Liver Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

Hepatitis B and C are the leading causes of liver disease in Saudi Arabia, accounting for over 75% of all cases. When doing business in Saudi Arabia, economic diversification and reform efforts to attract foreign investment are critical concerns. These aspects could boost Saudi Arabia's Liver Disease Therapeutics market.

Market Restraints

Due to the extensive spread of COVID-19 throughout the country, several liver transplant programmes in Saudi Arabia have reduced or temporarily ceased their transplant activity until further notice. Saudi Arabia's fragility in the non-oil sector, compounded by COVID-19, increases the danger to enterprises. These factors may deter new entrants into the Saudi Arabia Liver Disease Therapeutics market.

Competitive Landscape

Key Players

Tabuk Pharmaceuticals: Tabuk Pharmaceuticals is a Saudi Arabian pharmaceutical company that produces a range of liver therapeutics, including drugs for the treatment of liver cancer and hepatitis B
Jamjoom Pharma: Jamjoom Pharma is a Saudi Arabian pharmaceutical company that produces a range of liver therapeutics, including drugs for the treatment of liver cancer, hepatitis B and C, and liver cirrhosis
SPIMACO: SPIMACO is a Saudi Arabian pharmaceutical company that produces a range of liver therapeutics, including drugs for the treatment of liver cancer and hepatitis B
Al-Jazeera Pharmaceutical Industries: Al-Jazeera Pharmaceutical Industries is a Saudi Arabian pharmaceutical company that produces a range of liver therapeutics, including drugs for the treatment of liver cancer and liver cirrhosis
Global Pharma: Global Pharma is a Saudi Arabian pharmaceutical company that produces a range of liver therapeutics, including drugs for the treatment of liver cancer and hepatitis B

Recent Notable Updates

August 2021: Albireo Pharma, a firm developing innovative bile acid modulators for uncommon liver diseases, has completed an ex-US commercial distributor collaboration with Genpharm Services for the Gulf area. Bylvay, the first medicine licenced for progressive familial intrahepatic cholestasis, will be commercialised, and distributed in Saudi Arabia under the terms of the agreement (PFIC). Saudi Arabia has one of the world's highest rates of PFIC. Bylvay was recently licenced in the United States for the treatment of pruritus in all subtypes of PFIC and got European Marketing authorization for the same.

Healthcare Policies and Reimbursement Scenarios

In Saudi Arabia, the Saudi Food and Drug Authority (SFDA) is responsible for regulating the registration and approval of drugs, including those used for liver disease treatment. The SFDA follows a strict regulatory framework that ensures safety and efficacy of drugs. The Saudi Arabian government provides reimbursement for some liver disease treatments, including for hepatitis B and C. The New Saudi Health System (NSHS) allowed local and foreign insurance companies to deal with expatriates and citizens in the private healthcare sector.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.